Q-omics provides the consensus-scored MRPL12 profile across patient tissues and cancer cell-line models. MRPL12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MRPL12 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, MRPL12 RNA expression shows 19,061 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KIRP, and THYM as cancer lineages where MRPL12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL12 survival associations across molecular data types. MRPL12 RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL12 RNA expression–survival associations across cancer types. High MRPL12 expression shows unfavorable associations in KIRC, ACC, UVM, LUAD, KICH and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MRPL12 RNA expression.
This table summarizes MRPL12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MRPL12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL12 shows higher tumor expression in KIRP, STAD, BLCA, LUAD, LUSC and HNSC. The KIRP box plot shows higher MRPL12 RNA expression in tumor versus normal tissue (log2 FC = +0.861, t-test p < 0.001).
This table shows molecular features associated with MRPL12 in patient tissues and cancer cell lines. In patient samples, MRPL12 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SKIN.
